LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis

Recruiting Observational Study
Methamphetamine Use Disorder Methamphetamine-induced Psychosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 49
Sex
Male
Study type
Observational
Participants needed
120 (estimated)
Sponsor
Elazığ Mental Health and Diseases Hospital · Government
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This cross-sectional observational case-control study aimed to examined serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study also aimed to assessed systemic inflammation using the Aggregate I…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
1. For Methamphetamine Use Disorder (MUD) Group: \*Inclusion Criteria: * Diagnosis of MUD according to DSM-5-TR * Medication-free for at least one month prior to admission * Age ≥ 18 years and \<65 years * Provided informed consent For Methamphetamine Use Disorder (MUD) Group: …
Contacts

Mehmet Hamdi ÖRÜM, MD, Assoc. Prof., Psychiatrist

+905382207558

mhorum@hotmail.com

CONTACT